3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
49
NIH
13
NETWORK
12
INDUSTRY
3
Study Type
Observational
2
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
604
Carboplatin
372
Paclitaxel
282
Cisplatin
267
Gemcitabine
252
Pemetrexed
193
Bevacizumab
190
Docetaxel
185
Nivolumab
181
Injections
167
Cyclophosphamide
147
atezolizumab
138
Fluorouracil
133
Capecitabine
133
Oxaliplatin
132
Dexamethasone
127
Fulvestrant
113
durvalumab
112
130-nm albumin-bound paclitaxel
110
fludarabine
101
Cetuximab
100
Leucovorin
97
Rituximab
94
venetoclax
90
Lenalidomide
83
enzalutamide
77
Prednisone
76
Azacitidine
74
Irinotecan
72
Ipilimumab
72
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Watchful Waiting
×
1 year
×
Clear all
NCT02184416
2026-02-27
ADONIS
Pfizer
Completed
554 enrolled
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled
NCT07338968
2026-01-14
CoMpass
Aura Biosciences
Not yet recruiting
100 enrolled